PharmAkea Inc.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Bayer/Evotec Collaboration O

Celgene Corp. 's aggressive deal-making strategy could pay off in a big way over the next several years, bringing in billions of dollars in annual sales from new drugs to diversify revenue beyond its

As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in ot

Financings Biopharma financings in the last quarter of 2013 reached $6.4 billion, an increase of 39% over Q3’s $4.6 billion, thanks to a large boost from debt financings. The fourth quarter – the seco